RESEARCH AND DEVELOPMENT
CELONEX PHARMACEUTICALS AND CELONEX LIFE SCIENCE ARE LOCATED IN EDMONTON, ALBERTA.
The Life Science division specializes in the development of new technologies for
fast, ultra sensitive, and high-throughput genomics and proteomics analysis. Celonex
has developed a unique new microarray platform in CeramiChip™. This new platform
can be used for both DNA and protein microarray, and clearly surpasses glass-based
platforms in many respects. Using its unique microarray system, Celonex is the only
company worldwide that manufactures and commercializes various DNA microarrays for
functional genomic studies of many important human viruses, such as HIV1/2, human
herpes viruses (HHV1-8), etc. Celonex has also developed a non-enzymatic DNA amplification
technology that can efficiently intensify the detection signals on different genomics
and proteomics platforms. It can also be used for ultra sensitive detection in other
molecular or immunochemical assays. Furthermore, Celonex is a fast expanding company
that places an emphasis on proteomics and production of specific monoclonal antibodies
against the entire human proteins.
The Celonex Pharmaceuticals division has recently been created to discover new drug
targets and to develop more efficient drug delivery systems, using Celonex’s advanced
genomics and proteomics technologies and information. Our current focus is on hypertension
and its associated diseases, such as chronic high blood pressure, heart attack,
stroke, kidney failure, glaucoma, diabetes, etc. In the hope of finding new drug
targets for such diseases, Celonex continues to discover the structure of a small
molecule referred to as parathyroid hypertensive factor (PHF). This molecule has
been clinically linked to high blood pressure and has also been shown to directly
cause hypertension in a model organism.
Celonex is owned and managed by Triple Five®.
TripleFive Group of Companies, © 2008. All Rights Reserved.